Investment Rating - The investment rating for the company is "Accumulate" (maintained) [2] Core Views - The company is recognized as a leading innovator in the pharmaceutical sector, with significant advancements in its drug pipeline and commercialization efforts [7] - The approval of the new drug, Hydrochloride Jikaxitinib Tablets, marks a significant milestone as it is the first domestic JAK inhibitor approved for the treatment of myelofibrosis [7] - The company is expected to achieve substantial revenue growth, with projected revenues of 803 million RMB in 2025, 1.302 billion RMB in 2026, and 1.912 billion RMB in 2027, reflecting growth rates of 50.7%, 62.1%, and 46.9% respectively [6][8] Financial Performance and Forecast - Revenue for 2023 is projected at 386 million RMB, with a growth rate of 27.8% [6] - The company is expected to turn profitable by 2025, with a net profit of 21 million RMB, followed by 336 million RMB in 2026 and 711 million RMB in 2027 [6][8] - Earnings per share (EPS) is forecasted to improve from -1.09 RMB in 2023 to 2.69 RMB in 2027 [6][8] - The company’s return on equity (ROE) is expected to rise significantly, reaching 30.6% by 2027 [6][8]

Investment Rating - The investment rating for the company is upgraded to "Buy" [2] Core Views - The company is a leader in the corporate management training industry, actively refining its strategy and products while nurturing new talent to enhance overall operations [7] - The company has maintained a high dividend payout ratio, proposing a cash dividend of 10.00 yuan per 10 shares, totaling 1.19 billion yuan, which accounts for 90.74% of its net profit for the first half of 2025 [7] - The company aims to open 100 branches in key cities across the country within the next 3-5 years, leveraging AI to enhance its operational efficiency and educational effectiveness [7] Financial Performance - For the first half of 2025, the company reported a revenue of 344 million yuan, a year-over-year decrease of 11.68%, and a net profit of 131 million yuan, down 3.51% year-over-year [7] - The company’s gross margin improved to 79.77% in Q2 2025, an increase of 1.16 percentage points year-over-year, attributed to a decrease in the proportion of low-margin consulting services [7] - The company’s revenue is projected to grow from 672 million yuan in 2023 to 1.27 billion yuan in 2027, with a compound annual growth rate (CAGR) of 19.5% [6][8] Profit Forecast - The forecasted net profit for 2025 is 308 million yuan, with expected growth rates of 14.6%, 18.4%, and 22.8% for the years 2025, 2026, and 2027 respectively [6][7] - The earnings per share (EPS) is projected to increase from 1.86 yuan in 2023 to 3.75 yuan in 2027 [6][8] Market Performance - The company’s stock closed at 37.20 yuan as of August 12, 2025, with a price-to-earnings (PE) ratio of 14.4 for 2025 [2][6] - The company has shown a market performance of -6%, 3%, 12%, 21%, 30%, and 39% over the last 12 months compared to the CSI 300 index [4]

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [2] Core Views - The company reported a revenue of 9.855 billion yuan for the first half of 2025, representing a year-on-year increase of 30.9%, with a net profit of 1.002 billion yuan, up 41.35% year-on-year [8] - The all-terrain vehicle business continues to advance in high-end markets, with sales of 101,800 units and revenue of 4.731 billion yuan, a year-on-year increase of 33.95% [8] - The motorcycle business is showing synergy in domestic and international sales, with electric two-wheelers entering a new growth phase, achieving explosive growth with sales of 250,500 units and revenue of 872 million yuan, up 652.06% year-on-year [8] - The company expects net profits for 2025-2027 to be 1.875 billion, 2.368 billion, and 2.931 billion yuan, corresponding to PE ratios of 22, 17, and 14 times respectively, maintaining the "Accumulate" rating [8] Financial Performance Summary - Revenue forecast for 2023A to 2027E shows a growth from 12.11 billion yuan in 2023 to 26.43 billion yuan in 2027, with a compound annual growth rate (CAGR) of 17.5% [7] - Net profit is projected to grow from 1.008 billion yuan in 2023 to 2.931 billion yuan in 2027, with a CAGR of 23.8% [7] - Earnings per share (EPS) is expected to increase from 6.70 yuan in 2023 to 19.21 yuan in 2027 [7] Market Position and Strategy - The company has expanded its distribution network, adding 130 new channels in the first half of 2025, bringing the total to over 3,000 [8] - The company maintains a leading position in the all-terrain vehicle export market, with a strong market share in Europe [8] - The motorcycle segment has seen a total sales volume of 150,300 units in the first half of 2025, with domestic sales of 79,000 units and international sales of 71,300 units [8]

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [2] Core Views - The company achieved a revenue of 597 million yuan in the first half of 2025, representing a year-on-year increase of 10.32%, while the net profit attributable to shareholders was a loss of 14 million yuan, a reduction in loss by 12 million yuan [8] - The second quarter performance met expectations, with revenue of 378 million yuan, up 8.76% year-on-year, and a net profit of 18 million yuan, up 54.07% year-on-year [8] - The company has seen progress across multiple sectors, including PCB, semiconductor, and controllers, despite challenges in the photovoltaic sector [8] - The forecast for revenue from 2025 to 2027 is 1.817 billion yuan, 2.070 billion yuan, and 2.286 billion yuan respectively, with net profits of 178 million yuan, 234 million yuan, and 258 million yuan [8] Financial Performance Summary - Revenue for 2023 is projected at 1,648 million yuan, with a growth rate of 3.7%, while 2024 is expected to see a slight decline of 2.4% [7] - The net profit for 2023 is estimated at 215 million yuan, with a significant growth rate of 41.5% [7] - Earnings per share (EPS) for 2025 is projected to be 0.92 yuan, with a price-to-earnings (PE) ratio of 55.8 [7] - The return on equity (ROE) is expected to be 8.9% in 2025, increasing to 12.2% by 2027 [7] Market Performance - The company's stock has shown a performance of -8% over the last 12 months, compared to a 14% increase in the CSI 300 index [4]

Inflation Data - July CPI year-on-year growth remained stable at 2.7%, with a month-on-month increase slowing to 0.2%[4] - Core CPI year-on-year growth rose to 3.1%, marking a six-month high, with a month-on-month increase of 0.3%[4][6] - Energy CPI recorded a year-on-year decrease of -1.6%, with gasoline prices dropping to -9.5%[11] Tariff Impact - Tariffs have a moderate impact on commodity prices, with core commodity year-on-year growth increasing to 1.2%, up 0.5 percentage points from the previous month[12] - Used car prices saw the largest increase, rising 2 percentage points to 4.8% year-on-year, influenced by tariffs[12] - Prices for furniture and clothing showed a slight month-on-month decrease, indicating a milder tariff impact[12] Service Sector - Core service year-on-year growth remained stable at 3.6%, with medical services rising to 4.3%, hindering overall service inflation reduction[15] - Housing inflation remained steady, with owner-equivalent rent year-on-year growth slightly declining to 4.1%[15] Market Expectations - Following the inflation data release, the probability of a Federal Reserve rate cut in September increased to 94%, with an average of 2.4 cuts expected for the year[18] - Consumer inflation expectations fell, with one-year expectations dropping to 4.5% and five-year expectations to 3.4%[15][20] Risks - Risks include potential unexpected downturns in the U.S. economy and tighter monetary policy from the Federal Reserve[19]

Report Industry Investment Rating No information provided regarding the report industry investment rating. Core Viewpoints of the Report - Historically, convertible bonds with overseas - listed stocks rarely had successful downward revisions. From 2016 to now, among 36 convertible bonds with overseas - listed stocks, only 2 had downward - revision histories, namely Huayou Convertible Bond (Swiss GDR listed) and Electric Convertible Bond (Hong Kong listed) [4][8]. - Currently, there are 9 convertible bonds in the entire convertible bond market with shares circulating outside the A - share market. Among them, 5 companies are listed in Hong Kong, and Great Wall Motor also has shares circulating in the US OTC market. 4 companies have issued Swiss GDRs [4][7]. - Overall, after listing in Hong Kong or the US, due to the opposition of foreign investors, there may be some obstacles to the downward revision of convertible bonds. However, considering the downward - revision situation of Electric Convertible Bond, such convertible bonds still have the possibility of downward revision, but it may require the controlling shareholder to have a relatively large number of domestic and overseas equities and the convertible bonds to have been reduced for voting [4]. - Recently, the number of issuers submitting Hong Kong - listing plans in the convertible bond market has been increasing. Considering the more complex clause handling of convertible bonds after Hong Kong listing historically, some low - remaining - term targets may have opportunities to play with clauses, which is a potential "possible change" worthy of attention in the current market environment where the overall parity of convertible bonds has significantly increased [4]. Summary by Relevant Catalogs 1. Historical Downward - Revision Situations of Convertible Bonds with Overseas - Listed Stocks - There are 9 convertible bonds in the current convertible bond market with shares circulating outside the A - share market, including 5 Hong Kong - listed companies and 4 companies with Swiss GDR issuances [7][8]. - From 2016 to now, among 36 convertible bonds with overseas - listed stocks, only 2 had downward - revision histories. About 16 of these targets triggered downward revisions, among which 3 convertible bonds proposed downward revisions, but Fulai Convertible Bond failed in the downward - revision proposal. Among the remaining 13 convertible bonds, 7 have been delisted, and 6 are still in the market [8][9]. 1.1 Shanghai Electric: Shareholder Meetings Held in Both A - share and H - share Markets, with 25% of H - shareholders Opposing - Electric Convertible Bond was listed on the Shanghai Stock Exchange in February 2016 and delisted in 2021. In November 2018, the company's board of directors proposed a downward revision of the convertible bond. In the special resolution on voting to revise the conversion price of Electric Convertible Bond, nearly 100% of A - shareholders voted in favor, and 75% of H - shareholders voted in favor. Since the total number of favorable votes in both places exceeded two - thirds, the downward - revision proposal passed. Throughout its life cycle, Electric Convertible Bond only had this one downward revision and finally expired and was delisted [11][12]. - From the 2018 holder structure of Electric Convertible Bond, it can be inferred that the actual controller participated in the voting. From the shareholder structure disclosed by the Hong Kong Stock Exchange in the 2018 semi - annual report, neither the controlling shareholder nor foreign investors had the right to veto [15]. - Three points can be summarized from the case of Electric Convertible Bond: foreign investors are likely to vote against downward revisions; the successful downward revision of Electric Convertible Bond may be due to the controlling shareholder having a large proportion of voting rights in both A - shares and H - shares; if a convertible bond proposes a downward revision, it may require more than two - thirds of favorable votes from both A - shares and H - shares [18][19]. 1.2 Huayou Cobalt: No Separate Shareholder Meeting for GDR, Similar to Foreign Investors in A - shares - Since Huayou Cobalt issued GDRs, its holders need to exercise voting rights through custodians. In November 2024, only one A - share temporary shareholder meeting was held for the downward - revision vote. The participating equity was 560 million shares, accounting for 33.4% of the total share capital. The major shareholder did not participate in the voting, and the opposing votes were about 10%. Considering that Huayou Cobalt's GDRs accounted for less than 6% of the total share capital, foreign investors had relatively less say in the downward revision [20]. 2. Summary: Planning for Hong Kong Listing is a "Possible Change" for Convertible Bonds - After listing in Hong Kong or the US, due to the opposition of foreign investors, there may be some obstacles to the downward revision of convertible bonds. However, such convertible bonds still have the possibility of downward revision. Since 2025, the number of issuers submitting Hong Kong - listing plans in the convertible bond market has been increasing. Some low - remaining - term targets may have opportunities to play with clauses, but after the corresponding issuers' H - share listing, the opportunities for clause games may be fewer [22].

Core Insights - The automotive market is stabilizing due to the anti-involution trend, with July retail sales reaching 1.826 million units, a year-on-year increase of 6.3% but a month-on-month decrease of 12.4%. Cumulative retail sales for the year stand at 12.728 million units, reflecting a 10.1% year-on-year growth [1][7][15] - The intelligent driving index continues to rise, with the latest release of the VLA driver model by Li Auto, enhancing the human-like driving behavior of vehicles and allowing users to control driving through voice commands [4][22][32] - Investment recommendations include companies with strong positions in automotive intelligence and advanced software capabilities, such as Ruiming Technology, Daotong Technology, and others [4][38] Automotive Market Analysis - In July, the automotive market showed a "front low, middle high, and back flat" trend, with retail sales slightly above the historical high of 1.768 million units in July 2023, indicating a stable market environment [7][15] - The number of models with price reductions in July was 17, compared to 23 in the same month last year, suggesting a relatively stable pricing environment [4][7] - The penetration rate of new energy vehicles reached 54.0% in July, supported by policies such as tax exemptions and trade-in programs [15] Intelligent Driving Developments - The intelligent driving index reached 35.6 in June, with a month-on-month increase of 1.8 units, driven by the sales growth of high-intelligence models like Model Y and Wanjie M8 [22][24] - Li Auto's new i8 model, featuring the VLA driver model, is set to enhance user experience by allowing voice command control [4][32] Investment Recommendations - The report suggests focusing on companies that excel in automotive intelligence and software capabilities, including Ruiming Technology, Daotong Technology, and others [4][38]

Core Insights - The report maintains a positive outlook on the pharmaceutical and biotechnology sector, with a focus on raw material prices as of July 2025 [1][3] Hormonal Drug Price Situation - In July 2025, prices for hormonal drugs such as progesterone, medroxyprogesterone acetate, saponin, dexamethasone sodium phosphate, hydrocortisone, and acetate hydrocortisone remained stable month-on-month. Year-on-year, progesterone prices remained unchanged, while medroxyprogesterone acetate, saponin, dexamethasone sodium phosphate, hydrocortisone, acetate hydrocortisone, and saponin saw declines of 1.85%, 3.23%, 84.22%, 14.04%, 12.15%, and 5.66% respectively [6][10] Antibiotic Intermediate Price Situation - In July 2025, prices for antibiotic intermediates such as 4-AA remained stable month-on-month, while 7-ADCA, 7-ACA, 6-APA, and penicillin industrial salt saw decreases of 1.92%, 2.08%, 8.33%, and 7.89% respectively. Year-on-year, 7-ADCA, 7-ACA, 6-APA, 4-AA, and penicillin industrial salt prices fell by 1.92%, 4.08%, 45.00%, 13.92%, and 41.67% respectively [10][11] β-Lactam Antibiotic Price Situation - In July 2025, prices for β-lactam antibiotics such as cephalexin, ampicillin, cefotaxime sodium, and cefaclor remained stable month-on-month. However, ceftriaxone sodium, cefixime, and amoxicillin saw declines of 1.55%, 1.37%, and 11.36% respectively. Year-on-year, cephalexin, ampicillin, ceftriaxone sodium, cefotaxime sodium, cefixime, and amoxicillin prices decreased by 1.82%, 2.22%, 9.29%, 3.40%, 12.20%, and 35.00% respectively, while cefaclor saw an increase of 6.12% [15][17] Cardiovascular Drug Price Situation - In July 2025, prices for cardiovascular raw materials such as valsartan, irbesartan, telmisartan, lisinopril, enalapril maleate, and atorvastatin calcium remained stable month-on-month. Year-on-year, valsartan prices decreased by 1.54%, while the other drugs remained unchanged [19][20]

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [2] Core Views - The company reported a significant increase in revenue and net profit for the first half of 2025, with revenue approximately 14.644 billion yuan, a year-on-year increase of 25.25%, and net profit approximately 1.223 billion yuan, a year-on-year increase of 45.82% [7] - The company is expected to benefit from the trend of automotive intelligence, expanding its product matrix and accelerating its international strategy [7] - The forecasted revenue for 2025-2027 is 34.604 billion, 42.856 billion, and 52.517 billion yuan respectively, with corresponding net profits of 2.676 billion, 3.377 billion, and 4.190 billion yuan [7] Financial Performance - The company's revenue for 2023A was 21.908 billion yuan, with a growth rate of 46.7%, and is projected to grow at rates of 26.1%, 25.3%, 23.8%, and 22.5% for the following years [6][8] - The net profit for 2023A was 1.547 billion yuan, with a growth rate of 30.6%, projected to grow at rates of 29.6%, 33.5%, 26.2%, and 24.1% for the subsequent years [6][8] - The company's earnings per share (EPS) for 2025E is projected to be 4.82 yuan, with a price-to-earnings (PE) ratio of 22.0 [6][8] Business Segments - The smart cockpit business generated revenue of 9.459 billion yuan, a year-on-year increase of 18.76%, while the smart driving business saw revenue of 4.147 billion yuan, a year-on-year increase of 55.49% [7] - The connected business revenue was 1.038 billion yuan, showing a slight decrease of 2.11% year-on-year [7] Market Performance - The company's stock performance over the last 12 months showed a decline of 5%, while the benchmark index (CSI 300) increased by 9% [4]

离型膜进展顺利，复合集流体+载体铜箔弹性巨大 洁美科技(002859) | 投资评级:增持(维持) | | --- | 证券研究报告 其他电子Ⅱ / 公司点评 / 2025.08.12 | 基本数据 | 2025-08-11 | | --- | --- | | 收盘价(元) | 26.66 | | 流通股本(亿股) | 4.06 | | 每股净资产(元) | 6.72 | | 总股本(亿股) | 4.31 | 最近 12 月市场表现 -13% 7% 27% 47% 67% 87% 洁美科技 沪深300 上证指数 其他电子Ⅱ 分析师 张益敏 SAC 证书编号：S0160522070002 zhangym02@ctsec.com 分析师 黄梦龙 SAC 证书编号：S0160525070014 huangml@ctsec.com 相关报告 1. 《收入增长利润承压，离型膜进展顺利》 2025-04-30 2. 《新品研发挤压利润，离型膜进入业绩贡 献期》 2025-04-16 3. 《载带业务软复苏 膜材料产品高端化进 行中》 2024-09-04 核心观点 盈利预测 [币种Table_FinchinaSimple ...